← Back
Data updated: Jun 28, 2026
BIOCORRX PHARMS
Pharma Pharmaceuticals
BIOCORRX PHARMS is a pharmaceutical company with 1 FDA-approved products.
2018
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
FDA Novel Drug Designations
(2018) 1 Novel 1 First-in-Class 1 Priority Review 1 Fast Track
See 1 novel approval →
2018 LUCEMYRA (LOFEXIDINE HYDROCHLORIDE) First-in-Class · Priority Review · Fast Track
BIOCORRX PHARMS's Key Drugs
BIOCORRX PHARMS's core commercial portfolio centers on LUCEMYRA — its most strategically important drugs approved in the last 15 years.
BIOCORRX PHARMS's Recent FDA Approvals
New NDA/BLA approvals for BIOCORRX PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
BIOCORRX PHARMS's Therapeutic Areas
Disease areas where BIOCORRX PHARMS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
BIOCORRX PHARMS Pipeline Snapshot
Active clinical trials for BIOCORRX PHARMS across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LUCEMYRA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2018-05-16
- Latest
- 2024-09-05
- Applications
- 1